Post Profile






Related Posts


Tecfidera Improves MS Patients’ Work Productivity, Compared with Other Therapies, Study Shows

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Multiple sclerosis patients taking Tecfidera, or dimethyl fumarate, were more productive at work than those on Copaxone or beta-interferon therapies, according to a study. Tecfidera also increased patients’ quality of life, research...

Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multi

Business & Finance / Personal Finance : Savings Experiment

Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis - Offers a Broad Spectrum of Patients with Relapsing Forms of MS an Effective and Convenient Treatment Option - - Redu...

Latest Tecfidera and Tysabri Data Suggest Treatments Improve MS Outcomes When Used Early

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Real-world data of treatment with Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) in relapsing multiple sclerosis (MS) patients suggest that treatment at early disease stages improves outcomes and prevents disability develop...

Dimethyl Fumarate Considerably Reduces MS Relapses And Disability Progression

Health : Medical News Today

240 mg of Dimethyl Fumarate (BG-12) taken orally two or three times a day showed reduced relapses by about half in patients with relapsing-remitting multiple sclerosis (PRMS) compared to those on placebo, Biogen Idec announced after...

Alkermes Begins Phase 3 Study of ALKS 8700 as Relapsing MS Treatment

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Alkermes has started a Phase 3 clinical trial evaluating ALKS 8700, the oral monomethyl fumarate (MMF) prodrug it is developing for the treatment of relapsing forms of multiple sclerosis (MS). The multicenter, double-blind, active-c...

Comments


Copyright © 2016 Regator, LLC